

G Michael Felker

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5234545/g-michael-felker-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

354
papers

25,458
citations

80
h-index

151
g-index

439
ext. papers

31,217
ext. citations

8.4
avg, IF

6.79
L-index

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 354 | Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF.. <i>Circulation: Heart Failure</i> , 2022 , CIRCHEARTFAILURE121008970 | 7.6 | 0 |
| 353 | Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF: From the GUIDE-IT Trial.. <i>JACC: Heart Failure</i> , 2022 , 10, 266-275 | 7.9 | 1 |
| 352 | Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis.. <i>Journal of the American Heart Association</i> , 2022 , 11, e024833 | 6 | 0 |
| 351 | The influence of comorbidities on achieving an N-terminal pro-b-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial. <i>ESC Heart Failure</i> , 2021 , | 3.7 | 1 |
| 350 | Worsening renal function in acute heart failure in the context of diuretic response. <i>European Journal of Heart Failure</i> , 2021 , | 12.3 | 1 |
| 349 | Clinical Trajectory of Patients with a Worsening Heart Failure Event and Reduced Ventricular Ejection Fraction.. <i>American Heart Journal</i> , 2021 , 245, 110-110 | 4.9 | |
| 348 | Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021 , 9, 890-903 | 7.9 | 0 |
| 347 | Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , | 16.2 | 9 |
| 346 | Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1147-1155 | 12.3 | 4 |
| 345 | Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and | 12.3 | 143 |
| 344 | Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021 , 5, 447-455 | 3.1 | 1 |
| 343 | Universal Definition and Classification of Heart Failure. <i>Journal of Cardiac Failure</i> , 2021 , | 3.3 | 84 |
| 342 | Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart Failure. <i>JACC: Heart Failure</i> , 2021 , 9, 293-300 | 7.9 | 10 |
| 341 | The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF). <i>European Journal of Heart Failure</i> , 2021 , 23, 1052-1056 | 12.3 | 4 |
| 340 | Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations. <i>European Journal of Heart Failure</i> , 2021 , 23, 1076-1084 | 12.3 | 8 |
| 339 | Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021 , 10, e019712 | 6 | 1 |
| 338 | Mechanisms and Models in Heart Failure: A Translational Approach. <i>Circulation Research</i> , 2021 , 128, 1435-1450 | 14.5 | 6 |

| | | | |
|-----|---|------|-----|
| 337 | Association Between Angiotensin Receptor-Nepriylsin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021 , 14, e008410 | 7.6 | 3 |
| 336 | Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study. <i>Circulation</i> , 2021 , 143, 2316-2318 | 16.7 | 3 |
| 335 | Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure. <i>ESC Heart Failure</i> , 2021 , 8, 2608-2616 | 3.7 | 2 |
| 334 | Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. <i>Journal of Cardiac Failure</i> , 2021 , 27, 670-676 | 3.3 | 3 |
| 333 | The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial. <i>Journal of Cardiac Failure</i> , 2021 , 27, 1359-1366 | 3.3 | 0 |
| 332 | Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 97-108 | 15.1 | 25 |
| 331 | Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF. <i>Circulation</i> , 2021 , 144, 180-182 | 16.7 | 7 |
| 330 | Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2021 , 9, 127-136 | 7.9 | 17 |
| 329 | Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021 , 384, 105-116 | 59.2 | 164 |
| 328 | Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2021 , 9, 42-51 | 7.9 | 7 |
| 327 | Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis. <i>ESC Heart Failure</i> , 2021 , 8, 662-669 | 3.7 | 2 |
| 326 | Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study. <i>JACC: Heart Failure</i> , 2021 , 9, 146-157 | 7.9 | 5 |
| 325 | Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. <i>JACC: Heart Failure</i> , 2021 , 9, 1-12 | 7.9 | 10 |
| 324 | Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the RELAX-AHF-2 study. <i>European Journal of Heart Failure</i> , 2021 , 23, 58-67 | 12.3 | 5 |
| 323 | Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction: The CONNECT-HF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 314-323 | 27.4 | 8 |
| 322 | Circulating long chain acylcarnitines and outcomes in diabetic heart failure: an HF-ACTION clinical trial substudy. <i>Cardiovascular Diabetology</i> , 2021 , 20, 161 | 8.7 | 1 |
| 321 | Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction After a Recent Worsening Heart Failure Event. <i>Journal of the American Heart Association</i> , 2021 , 10, e021276 | 6 | 1 |
| 320 | Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure. <i>American Heart Journal</i> , 2021 , 239, 110-119 | 4.9 | 2 |

| | | | |
|-----|--|------|----|
| 319 | Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes.. <i>JACC: Heart Failure</i> , 2021 , | 7.9 | 4 |
| 318 | Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial. <i>Circulation: Heart Failure</i> , 2020 , 13, e006758 | 7.6 | 6 |
| 317 | Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2020 , 13, e006946 | 7.6 | 13 |
| 316 | Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2020 , 9, e012405 | 6 | 2 |
| 315 | Annexin A1 is a Potential Novel Biomarker of Congestion in Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2020 , 26, 727-732 | 3.3 | 1 |
| 314 | Splanchnic Nerve Block for Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2020 , 8, 742-752 | 7.9 | 18 |
| 313 | Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper. <i>JACC: Heart Failure</i> , 2020 , 8, 347-358 | 7.9 | 27 |
| 312 | Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-AHF-2 trial. <i>European Journal of Heart Failure</i> , 2020 , 22, 726-738 | 12.3 | 12 |
| 311 | Regional adiposity and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2020 , 22, 1540-1550 | 12.3 | 29 |
| 310 | Racial Differences in Diuretic Efficiency, Plasma Renin, and Rehospitalization in Subjects With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2020 , 13, e006827 | 7.6 | 7 |
| 309 | Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial. <i>European Journal of Heart Failure</i> , 2020 , 22, 1684-1693 | 12.3 | 19 |
| 308 | Provider Perspectives on the Feasibility and Utility of Routine Patient-Reported Outcomes Assessment in Heart Failure: A Qualitative Analysis. <i>Journal of the American Heart Association</i> , 2020 , 9, e013047 | 6 | 10 |
| 307 | Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF. <i>JACC: Heart Failure</i> , 2020 , 8, 329-340 | 7.9 | 61 |
| 306 | Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2020 , 5, 757-764 | 16.2 | 26 |
| 305 | Endpoints in Heart Failure Drug Development: History and Future. <i>JACC: Heart Failure</i> , 2020 , 8, 429-440 | 7.9 | 16 |
| 304 | Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1178-1195 | 15.1 | 61 |
| 303 | Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS-HF. <i>Journal of the American Heart Association</i> , 2020 , 9, e015752 | 6 | 5 |
| 302 | Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. <i>European Journal of Heart Failure</i> , 2020 , 22, 315-329 | 12.3 | 16 |

| | | | |
|-----|---|------|----|
| 301 | Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure?. <i>American Heart Journal</i> , 2020 , 220, 97-107 | 4.9 | 3 |
| 300 | Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2020 , 13, e007829 | 7.6 | 8 |
| 299 | Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , 2020 , 22, 2160-2171 | 12.3 | 24 |
| 298 | Biomarkers in Advanced Heart Failure: Implications for Managing Patients With Mechanical Circulatory Support and Cardiac Transplantation. <i>Circulation: Heart Failure</i> , 2020 , 13, e006840 | 7.6 | 1 |
| 297 | Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2. <i>JACC: Heart Failure</i> , 2020 , 8, 999-1008 | 7.9 | 0 |
| 296 | Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 2368-2378 | 15.1 | 16 |
| 295 | Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study. <i>Circulation: Heart Failure</i> , 2020 , 13, e007814 | 7.6 | 5 |
| 294 | Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure: The COSMIC-HF Trial. <i>Circulation: Heart Failure</i> , 2020 , 13, e008007 | 7.6 | 1 |
| 293 | Heart Failure Clinical Trial Operations During the COVID-19 Pandemic: Results From a Multicenter Survey. <i>Circulation: Heart Failure</i> , 2020 , 13, e007456 | 7.6 | 4 |
| 292 | Obese-Inflammatory Phenotypes in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020 , 13, e006414 | 7.6 | 14 |
| 291 | In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States. <i>JACC: Heart Failure</i> , 2020 , 8, 943-953 | 7.9 | 10 |
| 290 | Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. <i>European Journal of Heart Failure</i> , 2020 , 22, 2018-2025 | 12.3 | 10 |
| 289 | Racial Differences in Serial NT-proBNP Levels in Heart Failure Management: Insights From the GUIDE-IT Trial. <i>Circulation</i> , 2020 , 142, 1018-1020 | 16.7 | 4 |
| 288 | Challenges and Potential Improvements to Patient Access to Pharmaceuticals: Examples From Cardiology. <i>Circulation</i> , 2020 , 142, 790-798 | 16.7 | 3 |
| 287 | Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. <i>American Heart Journal</i> , 2020 , 220, 41-50 | 4.9 | 13 |
| 286 | Adverse Renal Response to Decongestion in the Obese Phenotype of Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2020 , 26, 101-107 | 3.3 | 14 |
| 285 | Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction 2020 , 520-548 | | |
| 284 | Heart Failure as a Consequence of Ischemic Heart Disease 2020 , 254-268.e6 | | 2 |

| | | | |
|-----|---|------|-----|
| 283 | Circulating Nephilysin in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020 , 8, 70-80 | 7.9 | 15 |
| 282 | Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 1472-1476 | 12.3 | 1 |
| 281 | Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 322, 1085-1095 | 27.4 | 199 |
| 280 | Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1205-1217 | 15.1 | 28 |
| 279 | Utilizing mobile technologies to improve physical activity and medication adherence in patients with heart failure and diabetes mellitus: Rationale and design of the TARGET-HF-DM Trial. <i>American Heart Journal</i> , 2019 , 211, 22-33 | 4.9 | 19 |
| 278 | Breastfeeding, Cellular Immune Activation, and Myocardial Recovery in Peripartum Cardiomyopathy. <i>JACC Basic To Translational Science</i> , 2019 , 4, 291-300 | 8.7 | 11 |
| 277 | Renal Effects of Intensive Volume Removal in Heart Failure Patients With Preexisting Worsening Renal Function. <i>Circulation: Heart Failure</i> , 2019 , 12, e005552 | 7.6 | 21 |
| 276 | Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2019 , 21, 1022-1031 | 12.3 | 14 |
| 275 | Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score. <i>European Journal of Heart Failure</i> , 2019 , 21, 770-778 | 12.3 | 13 |
| 274 | Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2019 , 25, 703-711 | 3.3 | 6 |
| 273 | Spirolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 1097-1105 | 3.8 | 14 |
| 272 | Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). <i>American Journal of Cardiology</i> , 2019 , 123, 1660-1666 | 3 | 4 |
| 271 | Design of a "Lean" Case Report Form for Heart Failure Therapeutic Development. <i>JACC: Heart Failure</i> , 2019 , 7, 913-921 | 7.9 | 3 |
| 270 | Effects of Serelaxin in Patients with Acute Heart Failure. <i>New England Journal of Medicine</i> , 2019 , 381, 716-726 | 59.2 | 92 |
| 269 | Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-AHF trial. <i>ESC Heart Failure</i> , 2019 , 6, 1188-1198 | 3.7 | 13 |
| 268 | Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 1561-1570 | 12.3 | 4 |
| 267 | Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy. <i>JACC: CardioOncology</i> , 2019 , 1, 273-279 | 3.8 | 3 |
| 266 | Clinical Implications of the New York Heart Association Classification. <i>Journal of the American Heart Association</i> , 2019 , 8, e014240 | 6 | 45 |

| | | | |
|-----|---|------|-----|
| 265 | Rhythm Control Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction: Insights From Get With The Guidelines-Heart Failure. <i>Journal of the American Heart Association</i> , 2019 , 8, e011560 | 6 | 27 |
| 264 | Maternal Obesity Affects Cardiac Remodeling and Recovery in Women with Peripartum Cardiomyopathy. <i>American Journal of Perinatology</i> , 2019 , 36, 476-483 | 3.3 | 10 |
| 263 | NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF. <i>JACC: Heart Failure</i> , 2019 , 7, 158-168 | 7.9 | 26 |
| 262 | High-Density Lipoprotein Particle Subfractions in Heart Failure With Preserved or Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 177-186 | 15.1 | 16 |
| 261 | History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2019 , 7, 47-55 | 7.9 | 6 |
| 260 | Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). | 6 | 7 |
| 259 | Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients. <i>Journal of the American Heart Association</i> , 2018 , 7, | 6 | 79 |
| 258 | Diuretic Treatment in Heart Failure. <i>New England Journal of Medicine</i> , 2018 , 378, 684-685 | 59.2 | 11 |
| 257 | Outpatient Worsening Heart Failure as a Target for Therapy: A Review. <i>JAMA Cardiology</i> , 2018 , 3, 252-256. | 6.2 | 43 |
| 256 | Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury. <i>Circulation</i> , 2018 , 137, 2016-2028 | 16.7 | 137 |
| 255 | Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. <i>International Journal of Cardiology</i> , 2018 , 253, 91-96 | 3.2 | 2 |
| 254 | Clinical Significance of Early Fluid and Weight Change During Acute Heart Failure Hospitalization. <i>Journal of Cardiac Failure</i> , 2018 , 24, 542-549 | 3.3 | 6 |
| 253 | Circulating T-Cell Subsets, Monocytes, and Natural Killer Cells in Peripartum Cardiomyopathy: Results From the Multicenter IPAC Study. <i>Journal of Cardiac Failure</i> , 2018 , 24, 33-42 | 3.3 | 9 |
| 252 | What's Next for Acute Heart Failure Research?. <i>Academic Emergency Medicine</i> , 2018 , 25, 85-93 | 3.4 | 6 |
| 251 | Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. <i>Clinical Research in Cardiology</i> , 2018 , 107, 170-181 | 6.1 | 22 |
| 250 | Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials. <i>JACC: Heart Failure</i> , 2018 , 6, 619-632 | 7.9 | 72 |
| 249 | Acute Decompensated Heart Failure 2018 , 233-240 | | |
| 248 | Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2018 , 20, 304-314 | 12.3 | 30 |

| | | | |
|-----|--|------|-----|
| 247 | Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 2551-2562 | 15.1 | 13 |
| 246 | Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 1764-1773 | 27.4 | 128 |
| 245 | High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network. <i>Journal of the American Heart Association</i> , 2018 , 7, e010364 | 6 | 13 |
| 244 | Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2018 , 24, 512-519 | 3.3 | 7 |
| 243 | Dose Response of β Blockers in Adrenergic Receptor Polymorphism Genotypes. <i>Circulation Genomic and Precision Medicine</i> , 2018 , 11, e002210 | 5.2 | 3 |
| 242 | Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF. <i>European Heart Journal</i> , 2018 , 39, 4255-4256 | 9.5 | 28 |
| 241 | Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure: Insights From the Get With The Guidelines-Heart Failure Registry. <i>Circulation: Heart Failure</i> , 2018 , 11, e004646 | 7.6 | 81 |
| 240 | Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes. <i>European Journal of Heart Failure</i> , 2018 , 20, 1031-1038 | 12.3 | 18 |
| 239 | A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. <i>European Journal of Heart Failure</i> , 2017 , 19, 1001-1010 | 12.3 | 57 |
| 238 | Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. <i>Clinical Research in Cardiology</i> , 2017 , 106, 444-456 | 6.1 | 4 |
| 237 | Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2017 , 6, | 6 | 44 |
| 236 | Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 1958-1966 | 27.4 | 201 |
| 235 | Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network). <i>American Journal of Cardiology</i> , 2017 , 120, 98-105 | 3 | 9 |
| 234 | Sildenafil Treatment in Heart Failure With Preserved Ejection Fraction: Targeted Metabolomic Profiling in the RELAX Trial. <i>JAMA Cardiology</i> , 2017 , 2, 896-901 | 16.2 | 19 |
| 233 | Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. <i>European Journal of Heart Failure</i> , 2017 , 19, 800-809 | 12.3 | 91 |
| 232 | Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). <i>European Heart Journal</i> , 2017 , 38, 2364-2373 | 9.5 | 72 |
| 231 | Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2017 , 135, e1054-e1091 | 16.7 | 274 |
| 230 | Myocardial Damage Detected by Late Gadolinium Enhancement Cardiac Magnetic Resonance Is Uncommon in Peripartum Cardiomyopathy. <i>Journal of the American Heart Association</i> , 2017 , 6, | 6 | 26 |

| | | | |
|-----|---|------|-----|
| 229 | Implications of Alternative Hepatorenal Prognostic Scoring Systems in Acute Heart Failure (from DOSE-AHF and ROSE-AHF). <i>American Journal of Cardiology</i> , 2017 , 119, 2003-2009 | 3 | 10 |
| 228 | Plasma Levels of MicroRNA-155 Are Upregulated with Long-Term Left Ventricular Assist Device Support. <i>ASAIO Journal</i> , 2017 , 63, 536-541 | 3.6 | 4 |
| 227 | Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction: Clinical Correlates and Association With Standard Heart Failure Severity Indices. <i>Circulation: Heart Failure</i> , 2017 , 10, e003878 | 7.6 | 29 |
| 226 | Novel approach to classifying patients with pulmonary arterial hypertension using cluster analysis. <i>Pulmonary Circulation</i> , 2017 , 7, 486-493 | 2.7 | 9 |
| 225 | Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. <i>American Heart Journal</i> , 2017 , 187, 62-69 | 4.9 | 6 |
| 224 | Comparison of Clinical Characteristics and Outcomes of Patients With Versus Without Diabetes Mellitus and With Versus Without Angina Pectoris (from the Duke Databank for Cardiovascular Disease). <i>American Journal of Cardiology</i> , 2017 , 119, 1703-1709 | 3 | 4 |
| 223 | Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial. <i>JACC: Heart Failure</i> , 2017 , 5, 1-13 | 7.9 | 58 |
| 222 | Inpatient Management of Heart Failure: Are We Shooting at the Right Target?. <i>Annals of Internal Medicine</i> , 2017 , 166, 223-224 | 8 | 2 |
| 221 | Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study. <i>JACC: Heart Failure</i> , 2017 , 5, 724-734 | 7.9 | 49 |
| 220 | Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 713-720 | 27.4 | 236 |
| 219 | Role of Volume Redistribution in the Congestion of Heart Failure. <i>Journal of the American Heart Association</i> , 2017 , 6, | 6 | 67 |
| 218 | Diuretic Treatment in Heart Failure. <i>New England Journal of Medicine</i> , 2017 , 377, 1964-1975 | 59.2 | 134 |
| 217 | Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2017 , 2, 950-958 | 16.2 | 114 |
| 216 | Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study. <i>Clinical Research in Cardiology</i> , 2017 , 106, 280-292 | 6.1 | 12 |
| 215 | Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1399-1406 | 15.1 | 114 |
| 214 | Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2016 , 22, 26-32 | 3.3 | 34 |
| 213 | The Potential Impact of Expanding Cardiac Rehabilitation in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 977-8 | 15.1 | 5 |
| 212 | Mode of Death After Acute Heart Failure Hospitalization - A Clue to Possible Mechanisms. <i>Circulation Journal</i> , 2016 , 80, 17-23 | 2.9 | 12 |

| | | | |
|-----|---|------|-----|
| 211 | The Effect of Omecamtiv Mecarbil on Symptoms of Heart Failure in the Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF). <i>Journal of Cardiac Failure</i> , 2016 , 22, S10-S11 | 3.3 | 3 |
| 210 | Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). <i>Circulation: Heart Failure</i> , 2016 , 9, | 7.6 | 36 |
| 209 | Implications of Using Different Definitions on Outcomes in Worsening Heart Failure. <i>Circulation: Heart Failure</i> , 2016 , 9, | 7.6 | 4 |
| 208 | Biomarker-based risk prediction in the community. <i>European Journal of Heart Failure</i> , 2016 , 18, 1342-1350. | 2.3 | 16 |
| 207 | Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. <i>Journal of Cardiac Failure</i> , 2016 , 22, 618-27 | 3.3 | 1 |
| 206 | Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure. <i>Gene Therapy</i> , 2016 , 23, 313-9 | 4 | 56 |
| 205 | Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , 2016 , 4, 68-77 | 7.9 | 32 |
| 204 | Serum Bicarbonate in Acute Heart Failure: Relationship to Treatment Strategies and Clinical Outcomes. <i>Journal of Cardiac Failure</i> , 2016 , 22, 738-42 | 3.3 | 12 |
| 203 | Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility With Mechanical Circulatory Support. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 291-9 | 15.1 | 98 |
| 202 | A Test in Context: Critical Evaluation of Natriuretic Peptide Testing in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 330-7 | 15.1 | 35 |
| 201 | Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1444-1455 | 15.1 | 142 |
| 200 | Coenzyme Q10 and Heart Failure: A State-of-the-Art Review. <i>Circulation: Heart Failure</i> , 2016 , 9, e002639. | 7.6 | 77 |
| 199 | Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. <i>Clinical Research in Cardiology</i> , 2016 , 105, 727-37 | 6.1 | 14 |
| 198 | Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. <i>Lancet, The</i> , 2016 , 387, 1178-86 | 4.0 | 275 |
| 197 | Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy: Results of the Multicenter IPAC Study. <i>JACC: Heart Failure</i> , 2016 , 4, 380-8 | 7.9 | 42 |
| 196 | Composite End Points in Acute Heart Failure Research: Data Simulations Illustrate the Limitations. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1356.e21-1356.e28 | 3.8 | 9 |
| 195 | Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow?. <i>Journal of Cardiac Failure</i> , 2016 , 22, 182-9 | 3.3 | 74 |
| 194 | Cardiac transplantation for older patients: Characteristics and outcomes in the septuagenarian population. <i>Journal of Heart and Lung Transplantation</i> , 2016 , 35, 362-369 | 5.8 | 21 |

| | | | |
|-----|---|------|-----|
| 193 | Clinical Implications of Cluster Analysis-Based Classification of Acute Decompensated Heart Failure and Correlation with Bedside Hemodynamic Profiles. <i>PLoS ONE</i> , 2016 , 11, e0145881 | 3.7 | 21 |
| 192 | Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. <i>Academic Emergency Medicine</i> , 2016 , 23, 922-31 | 3.4 | 7 |
| 191 | The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2016 , 18, 306-13 | 12.3 | 26 |
| 190 | Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials. <i>European Journal of Heart Failure</i> , 2016 , 18, 684-92 | 12.3 | 12 |
| 189 | Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2016 , 388, 2895-2903 | 4.0 | 158 |
| 188 | Pulmonary Hypertension in the Era of Mechanical Circulatory Support. <i>ASAIO Journal</i> , 2016 , 62, 505-12 | 3.6 | 8 |
| 187 | Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes: An Exploratory Analysis From the RELAX-AHF Trial. <i>JACC: Heart Failure</i> , 2016 , 4, 591-599 | 7.9 | 4.0 |
| 186 | Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure. <i>Journal of the American Heart Association</i> , 2016 , 5, e007577 | 6 | 101 |
| 185 | Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 500-8 | 27.4 | 327 |
| 184 | Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. <i>JACC: Heart Failure</i> , 2016 , 4, 726-35 | 7.9 | 27 |
| 183 | Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. <i>European Journal of Heart Failure</i> , 2016 , 18, 290-7 | 12.3 | 33 |
| 182 | Evaluation of the Incremental Prognostic Utility of Increasingly Complex Testing in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2015 , 8, 709-16 | 7.6 | 7 |
| 181 | Enrollment in Heart Failure Clinical Trials: Insights Into Which Entry Criteria Exclude Patients. <i>Journal of Cardiac Failure</i> , 2015 , 21, 608-9 | 3.3 | 2 |
| 180 | Reply: Mode of Death Prevention by Serelaxin. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 99 | 15.1 | |
| 179 | Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure). <i>JACC: Heart Failure</i> , 2015 , 3, 245-52 | 7.9 | 39 |
| 178 | Reply: applying cluster analysis to data of previously published chronic heart failure trials: systems biology and clinical phenotypes of heart failure syndrome. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1270-1271 | 15.1 | 1 |
| 177 | Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. <i>Circulation</i> , 2015 , 131, 1763-71 | 16.7 | 173 |
| 176 | Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials. <i>Circulation: Heart Failure</i> , 2015 , 8, 997-1005 | 7.6 | 19 |

| | | | |
|-----|---|------|-----|
| 175 | The Impact of Worsening Heart Failure in the United States. <i>Heart Failure Clinics</i> , 2015 , 11, 603-14 | 3.3 | 22 |
| 174 | Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2015 , 373, 2314-24 | 59.2 | 331 |
| 173 | Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). <i>JACC: Heart Failure</i> , 2015 , 3, 777-85 | 7.9 | 18 |
| 172 | CUPID 2: A Phase 2b Trial Investigating the Efficacy and Safety of the Intracoronary Administration of AAV1/SERCA2a in Patients with Advanced Heart Failure. <i>Journal of Cardiac Failure</i> , 2015 , 21, 939-940 | 3.3 | 3 |
| 171 | Early management of patients with acute heart failure: state of the art and future directions--a consensus document from the SAEM/HFSA acute heart failure working group. <i>Academic Emergency Medicine</i> , 2015 , 22, 94-112 | 3.4 | 30 |
| 170 | Early management of patients with acute heart failure: state of the art and future directions. A consensus document from the society for academic emergency medicine/heart failure society of America acute heart failure working group. <i>Journal of Cardiac Failure</i> , 2015 , 21, 27-43 | 3.3 | 55 |
| 169 | Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. <i>European Journal of Heart Failure</i> , 2015 , 17, 1133-43 | 12.3 | 66 |
| 168 | Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study. <i>European Journal of Heart Failure</i> , 2015 , 17, 1262-70 | 12.3 | 75 |
| 167 | In-hospital worsening heart failure. <i>European Journal of Heart Failure</i> , 2015 , 17, 1104-13 | 12.3 | 43 |
| 166 | Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). <i>American Heart Journal</i> , 2015 , 170, 298-305 | 4.9 | 32 |
| 165 | Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). <i>Circulation: Heart Failure</i> , 2015 , 8, 741-8 | 7.6 | 147 |
| 164 | Comparison of 2-Year Outcomes of Extended Criteria Cardiac Transplantation Versus Destination Left Ventricular Assist Device Therapy Using Continuous Flow. <i>American Journal of Cardiology</i> , 2015 , 116, 573-9 | 3 | 16 |
| 163 | Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. <i>JACC: Heart Failure</i> , 2015 , 3, 40-49 | 7.9 | 31 |
| 162 | The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease. <i>JACC: Heart Failure</i> , 2015 , 3, 9-16 | 7.9 | 110 |
| 161 | Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. <i>JACC: Heart Failure</i> , 2015 , 3, 97-107 | 7.9 | 75 |
| 160 | Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). <i>JACC: Heart Failure</i> , 2015 , 3, 193-201 | 7.9 | 62 |
| 159 | Effects of left ventricular assist device support on biomarkers of cardiovascular stress, fibrosis, fluid homeostasis, inflammation, and renal injury. <i>JACC: Heart Failure</i> , 2015 , 3, 30-39 | 7.9 | 54 |
| 158 | Natriuretic peptide-guided heart failure management. <i>European Heart Journal</i> , 2014 , 35, 16-24 | 9.5 | 134 |

| | | | |
|-----|---|------|-----|
| 157 | Decongestion in acute heart failure. <i>European Journal of Heart Failure</i> , 2014 , 16, 471-82 | 12.3 | 90 |
| 156 | The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure. <i>American Heart Journal</i> , 2014 , 167, 193-202.e1 | 4.9 | 40 |
| 155 | Clinical implications of chronic heart failure phenotypes defined by cluster analysis. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1765-74 | 15.1 | 132 |
| 154 | Characteristics and outcomes of patients with heart failure and discordant findings by right-sided heart catheterization and cardiopulmonary exercise testing. <i>American Journal of Cardiology</i> , 2014 , 114, 1059-64 | 3 | 11 |
| 153 | Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. <i>JACC: Heart Failure</i> , 2014 , 2, 457-65 | 7.9 | 84 |
| 152 | Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1591-8 | 15.1 | 50 |
| 151 | Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b). <i>JACC: Heart Failure</i> , 2014 , 2, 84-92 | 7.9 | 100 |
| 150 | Liver function, in-hospital, and post-discharge clinical outcome in patients with acute heart failure--results from the relaxin for the treatment of patients with acute heart failure study. <i>Journal of Cardiac Failure</i> , 2014 , 20, 407-13 | 3.3 | 31 |
| 149 | Charting a roadmap for heart failure biomarker studies. <i>JACC: Heart Failure</i> , 2014 , 2, 477-88 | 7.9 | 54 |
| 148 | Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. <i>JACC: Heart Failure</i> , 2014 , 2, 260-8 | 7.9 | 79 |
| 147 | Improving care for patients with acute heart failure: before, during and after hospitalization. <i>ESC Heart Failure</i> , 2014 , 1, 110-145 | 3.7 | 153 |
| 146 | Valvular heart disease in patients supported with left ventricular assist devices. <i>Circulation: Heart Failure</i> , 2014 , 7, 215-22 | 7.6 | 37 |
| 145 | Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. <i>European Heart Journal</i> , 2014 , 35, 1041-50 | 9.5 | 72 |
| 144 | Reply: predicting sudden cardiac death in heart failure. <i>JACC: Heart Failure</i> , 2014 , 2, 673 | 7.9 | 1 |
| 143 | Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF. <i>European Journal of Heart Failure</i> , 2014 , 16, 1230-40 | 12.3 | 95 |
| 142 | Fluid removal in acute heart failure: diuretics versus devices. <i>Current Opinion in Critical Care</i> , 2014 , 20, 478-83 | 3.5 | 7 |
| 141 | Acute Decompensated Heart Failure 2014 , 166-171 | | |
| 140 | High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. <i>Journal of Cardiac Failure</i> , 2014 , 20, 319-26 | 3.3 | 37 |

| | | | |
|-----|---|------|-----|
| 139 | Thrombolytic therapy for thrombosis of continuous flow ventricular assist devices. <i>Journal of Cardiac Failure</i> , 2014 , 20, 91-7 | 3.3 | 48 |
| 138 | Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 853-71 | 15.1 | 80 |
| 137 | Approaches to decongestion in patients with acute decompensated heart failure. <i>Current Cardiology Reports</i> , 2013 , 15, 335 | 4.2 | 5 |
| 136 | Cardiohepatic interactions in heart failure: an overview and clinical implications. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 2397-2405 | 15.1 | 157 |
| 135 | Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial. <i>Circulation: Heart Failure</i> , 2013 , 6, 1087-94 | 7.6 | 22 |
| 134 | Learning from recent trials and shaping the future of acute heart failure trials. <i>American Heart Journal</i> , 2013 , 166, 629-35 | 4.9 | 21 |
| 133 | Noncardiac comorbidities and acute heart failure patients. <i>Heart Failure Clinics</i> , 2013 , 9, 359-67, vii | 3.3 | 37 |
| 132 | Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. <i>European Heart Journal</i> , 2013 , 34, 3128-36 | 9.5 | 48 |
| 131 | Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2013 , 15, 456-64 | 12.3 | 32 |
| 130 | 2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure: a joint report of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Foundation Appropriate Use Criteria Task Force. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 2307-31 | 15.1 | 112 |
| 129 | Patient- and trial-specific barriers to participation in cardiovascular randomized clinical trials. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 762-9 | 15.1 | 52 |
| 128 | Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 1268-77 | 27.4 | 762 |
| 127 | Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 196-206 | 15.1 | 325 |
| 126 | Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. <i>Lancet, The</i> , 2013 , 381, 29-39 | 40 | 693 |
| 125 | Dysphagia in the setting of left ventricular assist device hemolysis. <i>ASAIO Journal</i> , 2013 , 59, 322-3 | 3.6 | 5 |
| 124 | Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 310, 2533-43 | 27.4 | 322 |
| 123 | Is there a rationale for antiplatelet therapy in acute heart failure?. <i>Circulation: Heart Failure</i> , 2013 , 6, 869-76 | 7.6 | 4 |
| 122 | Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening. <i>Journal of the American Heart Association</i> , 2013 , 2, e000399 | 6 | 58 |

| | | | |
|-----|--|------|-----|
| 121 | Ten-year experience with extended criteria cardiac transplantation. <i>Circulation: Heart Failure</i> , 2013 , 6, 1230-8 | 7.6 | 25 |
| 120 | Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes. <i>Circulation: Heart Failure</i> , 2013 , 6, 1172-9 | 7.6 | 95 |
| 119 | Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy. <i>European Journal of Heart Failure</i> , 2013 , 15, 258-66 | 12.3 | 34 |
| 118 | Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure. <i>Circulation: Heart Failure</i> , 2013 , 6, 240-5 | 7.6 | 111 |
| 117 | Significance of hyponatremia in heart failure. <i>Heart Failure Reviews</i> , 2012 , 17, 17-26 | 5 | 34 |
| 116 | Ultrafiltration in decompensated heart failure with cardiorenal syndrome. <i>New England Journal of Medicine</i> , 2012 , 367, 2296-304 | 59.2 | 577 |
| 115 | Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. <i>European Journal of Heart Failure</i> , 2012 , 14, 1257-64 | 12.3 | 82 |
| 114 | Design of the RELAXin in acute heart failure study. <i>American Heart Journal</i> , 2012 , 163, 149-55.e1 | 4.9 | 53 |
| 113 | Recurrence of heart failure symptoms after LVAD placement due to bradycardia-induced inflow obstruction. <i>Journal of Heart and Lung Transplantation</i> , 2012 , 31, 111-3 | 5.8 | 1 |
| 112 | Hyponatremia and long-term outcomes in chronic heart failure--an observational study from the Duke Databank for Cardiovascular Diseases. <i>Journal of Cardiac Failure</i> , 2012 , 18, 74-81 | 3.3 | 44 |
| 111 | Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network. <i>Journal of Cardiac Failure</i> , 2012 , 18, 176-82 | 2.3 | 72 |
| 110 | Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure. <i>American Heart Journal</i> , 2012 , 164, 862-8 | 4.9 | 30 |
| 109 | Diuretics and ultrafiltration in acute decompensated heart failure. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 2145-53 | 15.1 | 116 |
| 108 | Obesity and the response to intensified diuretic treatment in decompensated heart failure: a DOSE trial substudy. <i>Journal of Cardiac Failure</i> , 2012 , 18, 837-44 | 3.3 | 8 |
| 107 | Novel biomarkers in chronic heart failure. <i>Nature Reviews Cardiology</i> , 2012 , 9, 347-59 | 14.8 | 80 |
| 106 | Loop diuretics in heart failure. <i>Heart Failure Reviews</i> , 2012 , 17, 305-11 | 5 | 26 |
| 105 | Management of the cardiorenal syndrome in acute heart failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2012 , 14, 342-55 | 2.1 | 4 |
| 104 | Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation. <i>Clinical Research in Cardiology</i> , 2012 , 101, 663-72 | 6.1 | 35 |

| | | | |
|-----|---|------|------|
| 103 | Comparison of Clinical characteristics and long-term outcomes of patients with ischemic cardiomyopathy with versus without angina pectoris (from the Duke Databank for Cardiovascular Disease). <i>American Journal of Cardiology</i> , 2012 , 109, 1272-7 | 3 | 25 |
| 102 | Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012 , 5, 594-600 | 5.8 | 39 |
| 101 | Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. <i>Circulation: Heart Failure</i> , 2012 , 5, 72-8 | 7.6 | 173 |
| 100 | Link between decisions regarding resuscitation and preferences for quality over length of life with heart failure. <i>European Journal of Heart Failure</i> , 2012 , 14, 45-53 | 12.3 | 24 |
| 99 | Reduction in body weight but worsening renal function with late ultrafiltration for treatment of acute decompensated heart failure. <i>Cardiology</i> , 2012 , 123, 145-53 | 1.6 | 7 |
| 98 | Decision making in advanced heart failure: a scientific statement from the American Heart Association. <i>Circulation</i> , 2012 , 125, 1928-52 | 16.7 | 511 |
| 97 | Etiology and overview of heart failure 2012 , 6-17 | | 1 |
| 96 | Diagnosis and Management of Acute Heart Failure Syndromes 2012 , 517-542 | | 4 |
| 95 | Biomarkers as surrogate end points in heart failure trials. <i>Heart Failure Clinics</i> , 2011 , 7, 501-7 | 3.3 | 6 |
| 94 | Effect of nesiritide in patients with acute decompensated heart failure. <i>New England Journal of Medicine</i> , 2011 , 365, 32-43 | 59.2 | 930 |
| 93 | Patterns of leukocyte counts on admissions for acute heart failure--presentation and outcome--results from a community based registry. <i>International Journal of Cardiology</i> , 2011 , 148, 17-22 | 3.2 | 16 |
| 92 | Natriuretic Peptide-guided therapy for heart failure. <i>Circulation Journal</i> , 2011 , 75, 2031-7 | 2.9 | 11 |
| 91 | Clinical impact of concomitant tricuspid valve procedures during left ventricular assist device implantation. <i>Annals of Thoracic Surgery</i> , 2011 , 92, 1414-8; discussion 1418-9 | 2.7 | 51 |
| 90 | Diuretic strategies in patients with acute decompensated heart failure. <i>New England Journal of Medicine</i> , 2011 , 364, 797-805 | 59.2 | 1012 |
| 89 | Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF. <i>Clinical Research in Cardiology</i> , 2011 , 100, 745-53 | 6.1 | 11 |
| 88 | Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. <i>European Journal of Heart Failure</i> , 2011 , 13, 961-7 | 12.3 | 83 |
| 87 | Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims. <i>Circulation: Heart Failure</i> , 2011 , 4, 628-36 | 7.6 | 161 |
| 86 | Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices. <i>Circulation: Heart Failure</i> , 2011 , 4, 779-84 | 7.6 | 201 |

| | | | |
|----|--|------|-----|
| 85 | Thromboembolism and antithrombotic therapy in patients with heart failure in sinus rhythm: current status and future directions. <i>Circulation: Heart Failure</i> , 2011 , 4, 361-8 | 7.6 | 25 |
| 84 | A global rank end point for clinical trials in acute heart failure. <i>Circulation: Heart Failure</i> , 2010 , 3, 643-6 | 7.6 | 54 |
| 83 | Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. <i>European Journal of Heart Failure</i> , 2010 , 12, 1130-9 | 12.3 | 73 |
| 82 | Too much, too little, or just right?: untangling endogenous erythropoietin in heart failure. <i>Circulation</i> , 2010 , 121, 191-3 | 16.7 | 1 |
| 81 | Red blood cell distribution width and 1-year mortality in acute heart failure. <i>European Journal of Heart Failure</i> , 2010 , 12, 129-36 | 12.3 | 170 |
| 80 | Low lymphocyte ratio as a novel prognostic factor in acute heart failure: results from the Pre-RELAX-AHF study. <i>Cardiology</i> , 2010 , 117, 190-6 | 1.6 | 13 |
| 79 | A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. <i>Kidney International</i> , 2010 , 77, 239-46 | 9.9 | 48 |
| 78 | Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1071-8 | 15.1 | 301 |
| 77 | Acute heart failure: multiple clinical profiles and mechanisms require tailored therapy. <i>International Journal of Cardiology</i> , 2010 , 144, 175-9 | 3.2 | 51 |
| 76 | Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure. <i>Journal of Cardiac Failure</i> , 2010 , 16, 230-8 | 3.3 | 272 |
| 75 | Prospective evaluation of the association between cardiac troponin T and markers of disturbed erythropoiesis in patients with heart failure. <i>American Heart Journal</i> , 2010 , 160, 1142-8 | 4.9 | 14 |
| 74 | Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. <i>Circulation: Heart Failure</i> , 2010 , 3, 314-25 | 7.6 | 120 |
| 73 | Biomarker guided therapy for heart failure: focus on natriuretic peptides. <i>Heart Failure Reviews</i> , 2010 , 15, 351-70 | 5 | 13 |
| 72 | Multi-marker strategies in heart failure: clinical and statistical approaches. <i>Heart Failure Reviews</i> , 2010 , 15, 343-9 | 5 | 23 |
| 71 | United States stock market performance and acute myocardial infarction rates in 2008-2009 (from the Duke Databank for Cardiovascular Disease). <i>American Journal of Cardiology</i> , 2010 , 106, 1545-9 | 3 | 21 |
| 70 | Diuretic management in heart failure. <i>Congestive Heart Failure</i> , 2010 , 16 Suppl 1, S68-72 | | 34 |
| 69 | Clinical Trial Design in Heart Failure 2010 , 570-593 | | |
| 68 | Acute Decompensated Heart Failure 2010 , 157-162 | | |

| | | | |
|----|--|------|-----|
| 67 | Rapid clinical assessment of patients with acute heart failure: first blood pressure and oxygen saturation--is that all we need?. <i>Cardiology</i> , 2009 , 114, 75-82 | 1.6 | 5 |
| 66 | Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. <i>European Journal of Heart Failure</i> , 2009 , 11, 170-7 | 12.3 | 247 |
| 65 | Vasodilators in the treatment of acute heart failure: what we know, what we don't. <i>Heart Failure Reviews</i> , 2009 , 14, 299-307 | 5 | 45 |
| 64 | Relaxin, a pleiotropic vasodilator for the treatment of heart failure. <i>Heart Failure Reviews</i> , 2009 , 14, 321-9 | 9 | 92 |
| 63 | How to use diuretics in heart failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2009 , 11, 426-32 | 2.1 | 7 |
| 62 | Early worsening heart failure in patients admitted with acute heart failure--a new outcome measure associated with long-term prognosis?. <i>Fundamental and Clinical Pharmacology</i> , 2009 , 23, 633-9 | 3.1 | 30 |
| 61 | Changes in Dyspnea during Treatment of Acute Heart Failure Are Correlated with Clinical Signs, Rehospitalizations and Mortality. Results from the Pre-RELAX-AHF Trial. <i>Journal of Cardiac Failure</i> , 2009 , 15, S62-S63 | 3.3 | 2 |
| 60 | Relationship between anemia and health care costs in heart failure. <i>Journal of Cardiac Failure</i> , 2009 , 15, 843-9 | 3.3 | 12 |
| 59 | Prospective assessment of the occurrence of anemia in patients with heart failure: results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry. <i>American Heart Journal</i> , 2009 , 157, 926-32 | 4.9 | 39 |
| 58 | Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. <i>American Heart Journal</i> , 2009 , 157, 957-70 | 4.9 | 43 |
| 57 | Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. <i>American Heart Journal</i> , 2009 , 158, 422-30 | 4.9 | 261 |
| 56 | N-terminal pro-brain natriuretic peptide and exercise capacity in chronic heart failure: data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study. <i>American Heart Journal</i> , 2009 , 158, S37-44 | 4.9 | 22 |
| 55 | Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure. <i>American Heart Journal</i> , 2009 , 158, 965-71 | 4.9 | 35 |
| 54 | Impact of left ventricular assist device bridging on posttransplant outcomes. <i>Annals of Thoracic Surgery</i> , 2009 , 88, 1457-61; discussion 1461 | 2.7 | 32 |
| 53 | End points for clinical trials in acute heart failure syndromes. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 2248-58 | 15.1 | 84 |
| 52 | Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. <i>Lancet</i> , 2009 , 373, 1429-39 | 40 | 334 |
| 51 | Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?. <i>Circulation: Heart Failure</i> , 2009 , 2, 56-62 | 7.6 | 216 |
| 50 | Using genetic information to select treatment for patients with heart failure: has the time come?. <i>Personalized Medicine</i> , 2009 , 6, 385-392 | 2.2 | |

| | | | |
|----|--|------|-----|
| 49 | Infectious complications in extended criteria heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2008 , 27, 1217-21 | 5.8 | 16 |
| 48 | The pathophysiology of acute heart failure--is it all about fluid accumulation?. <i>American Heart Journal</i> , 2008 , 155, 9-18 | 4.9 | 142 |
| 47 | A global ranking approach to end points in trials of mechanical circulatory support devices. <i>Journal of Cardiac Failure</i> , 2008 , 14, 368-72 | 3.3 | 31 |
| 46 | Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF). <i>Journal of Cardiac Failure</i> , 2008 , 14, 777-84 | 3.3 | 36 |
| 45 | Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 299, 2533-42 | 27.4 | 178 |
| 44 | Hyponatraemia in acute heart failure is a marker of increased mortality but not when associated with hyperglycaemia. <i>European Journal of Heart Failure</i> , 2008 , 10, 196-200 | 12.3 | 22 |
| 43 | Inotropes in the management of acute heart failure. <i>Critical Care Medicine</i> , 2008 , 36, S106-11 | 1.4 | 99 |
| 42 | Advances in the surgical treatment of heart failure. <i>Current Opinion in Cardiology</i> , 2008 , 23, 249-53 | 2.1 | 18 |
| 41 | Acute heart failure associated with high admission blood pressure--a distinct vascular disorder?. <i>European Journal of Heart Failure</i> , 2007 , 9, 178-83 | 12.3 | 37 |
| 40 | Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 40-7 | 15.1 | 630 |
| 39 | Inflammatory biomarkers in heart failure. <i>Congestive Heart Failure</i> , 2006 , 12, 324-8 | | 54 |
| 38 | Natriuretic peptides in the diagnosis and management of heart failure. <i>Cmaj</i> , 2006 , 175, 611-7 | 3.5 | 71 |
| 37 | Anaemia and coronary artery disease severity in patients with heart failure. <i>European Journal of Heart Failure</i> , 2006 , 8, 54-7 | 12.3 | 8 |
| 36 | Marginal cardiac allografts do not have increased primary graft dysfunction in alternate list transplantation. <i>Circulation</i> , 2006 , 114, 127-32 | 16.7 | 103 |
| 35 | Topical anesthesia with EMLA reduces pain during endomyocardial biopsy: a randomized trial. <i>Journal of Heart and Lung Transplantation</i> , 2006 , 25, 1164-6 | 5.8 | 2 |
| 34 | Same bridge, new destinations rethinking paradigms for mechanical cardiac support in heart failure. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 930-2 | 15.1 | 41 |
| 33 | Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial. <i>Journal of Cardiac Failure</i> , 2006 , 12, 684-8 | 3.3 | 34 |
| 32 | The Valsalva maneuver: a bedside "biomarker" for heart failure. <i>American Journal of Medicine</i> , 2006 , 119, 117-22 | 2.4 | 67 |

| | | | |
|----|--|------|-----|
| 31 | Anemia in patients with heart failure and preserved systolic function. <i>American Heart Journal</i> , 2006 , 151, 457-62 | 4.9 | 74 |
| 30 | Implantable left ventricular assist devices: new hope for patients with end-stage heart failure. <i>North Carolina Medical Journal</i> , 2006 , 67, 110-5 | 0.6 | 8 |
| 29 | The African-American heart failure trial: a new look at old drugs. <i>Future Cardiology</i> , 2005 , 1, 311-3 | 1.3 | |
| 28 | Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. <i>Circulation</i> , 2005 , 111, 2454-60 | 16.7 | 376 |
| 27 | Recurrence of cardiac sarcoidosis in a heart transplant recipient. <i>Journal of Heart and Lung Transplantation</i> , 2005 , 24, 1988-90 | 5.8 | 74 |
| 26 | Outcomes with an alternate list strategy for heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2005 , 24, 1781-6 | 5.8 | 61 |
| 25 | B-type natriuretic peptide - a biomarker for all seasons?. <i>New England Journal of Medicine</i> , 2004 , 350, 718-20 | 59.2 | 72 |
| 24 | Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. <i>American Journal of Cardiology</i> , 2004 , 93, 783-5 | 3 | 43 |
| 23 | Anemia as a risk factor and therapeutic target in heart failure. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 959-66 | 15.1 | 192 |
| 22 | Risk stratification after hospitalization for decompensated heart failure. <i>Journal of Cardiac Failure</i> , 2004 , 10, 460-6 | 3.3 | 257 |
| 21 | Mortality in primary and secondary myocarditis. <i>American Heart Journal</i> , 2004 , 147, 746-50 | 4.9 | 26 |
| 20 | Left ventricular assist devices as destination therapy for end-stage heart failure. <i>American Heart Journal</i> , 2004 , 148, 252-3 | 4.9 | 2 |
| 19 | The impact of arrhythmias in acute heart failure. <i>Journal of Cardiac Failure</i> , 2004 , 10, 279-84 | 3.3 | 51 |
| 18 | Cardiac transplantation at Duke University Medical Center. <i>Clinical Transplants</i> , 2004 , 235-41 | | 2 |
| 17 | Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. <i>American Journal of Cardiology</i> , 2003 , 91, 169-74 | 3 | 57 |
| 16 | Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. <i>American Journal of Cardiology</i> , 2003 , 91, 538-43 | 3 | 531 |
| 15 | Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. <i>American Journal of Cardiology</i> , 2003 , 92, 625-8 | 3 | 167 |
| 14 | Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. <i>Journal of the American College of Cardiology</i> , 2003 , 41, 997-1003 | 15.1 | 401 |

| | | | |
|----|---|------|------|
| 13 | The problem of decompensated heart failure: nomenclature, classification, and risk stratification. <i>American Heart Journal</i> , 2003 , 145, S18-25 | 4.9 | 128 |
| 12 | A bridge for the 21st century in heart transplantation?. <i>American Heart Journal</i> , 2003 , 145, 198-9 | 4.9 | 5 |
| 11 | Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. <i>Circulation</i> , 2002 , 105, 1663-8 | 16.7 | 115 |
| 10 | A standardized definition of ischemic cardiomyopathy for use in clinical research. <i>Journal of the American College of Cardiology</i> , 2002 , 39, 210-8 | 15.1 | 418 |
| 9 | Rational use of inotropic therapy in heart failure. <i>Current Cardiology Reports</i> , 2001 , 3, 108-13 | 4.2 | 19 |
| 8 | Inotropic therapy for heart failure: an evidence-based approach. <i>American Heart Journal</i> , 2001 , 142, 393-401 | 4.9 | 192 |
| 7 | Between Scylla and Charybdis: The choice of inotropic agent for decompensated heart failure. <i>American Heart Journal</i> , 2001 , 142, 932-3 | 4.9 | 7 |
| 6 | Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. <i>New England Journal of Medicine</i> , 2000 , 342, 1077-84 | 59.2 | 1182 |
| 5 | Myocarditis and long-term survival in peripartum cardiomyopathy. <i>American Heart Journal</i> , 2000 , 140, 785-91 | 4.9 | 127 |
| 4 | Echocardiographic findings in fulminant and acute myocarditis. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 227-32 | 15.1 | 274 |
| 3 | The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1,278 patients. <i>Medicine (United States)</i> , 1999 , 78, 270-83 | 1.8 | 166 |
| 2 | Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. <i>Cancer Chemotherapy and Pharmacology</i> , 1993 , 32, 471-6 | 3.5 | 54 |
| 1 | Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. <i>Journal of the National Cancer Institute</i> , 1992 , 84, 1926-31 | 9.7 | 78 |